Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin

Published: Sep 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INDIANAPOLIS & HAYWARD, Calif.--(BUSINESS WIRE)--Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc.), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and Aradigm Corporation (OTC BB: ARDM.OB), an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, today announced that they have entered into a broad manufacturing services agreement whereby Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin®. Pulmaquin is Aradigm’s proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

Help employers find you! Check out all the jobs and post your resume.

Back to news